Trexquant Investment’s Niagen Bioscience NAGE Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
– Sell
-243,186
Closed -$776K – 2337
2026
Q2
$776K Sell
243,186
-333,630
-58% -$1.35M ﹤0.01% 1538
2026
Q1
$2.54M Buy
576,816
+140,484
+32% +$759K 0.02% 903
2025
Q4
$2.78M Sell
436,332
-6,127
-1% -$42.6K 0.02% 859
2025
Q3
$4.13M Buy
442,459
+308,572
+230% +$3.12M 0.04% 619
2025
Q2
$1.93M Sell
133,887
-75,899
-36% -$749K 0.02% 900
2025
Q1
$1.45M Buy
209,786
+182,603
+672% +$1.15M 0.02% 974
2024
Q4
$144K Buy
+27,183
New +$149K ﹤0.01% 1495
2018
Q1
– Sell
-43,748
Closed -$257K – 1441
2017
Q4
$257K Buy
+43,748
New +$236K 0.03% 815

Other funds holding NAGE

Trexquant Investment's NAGE Position: Q3 2026 in Review

Trexquant Investment sold out of Niagen Bioscience (NAGE) in Q3 2026, closing a stake of 243,186 shares — an estimated $776K sold.

Trexquant Investment first reported a position in NAGE in Q4 2017 and held it in 8 quarters. The position peaked at $4.13M in Q3 2025. 124 funds tracked by Wall St. Rank hold NAGE as of Q3 2026.

  • Trexquant Investment reported no remaining Niagen Bioscience position as of Q3 2026 after selling out during the quarter.
  • Trexquant Investment sold 243,186 Niagen Bioscience shares in Q3 2026, an estimated $776K.
  • Trexquant Investment first reported a position in Niagen Bioscience in Q4 2017 and held it in 8 quarters.
  • Trexquant Investment's Niagen Bioscience position peaked at $4.13M in Q3 2025.
  • 124 funds tracked by Wall St. Rank held Niagen Bioscience as of Q3 2026.

Based on Trexquant Investment's 13F filing for Q3 2026, filed 16 Nov 2026.